Acrolein Can Cause Cardiovascular Disease: A Review

Cardiovascular Toxicology

Volumn 17, Issue 3, 2017, Pages 227-236

  Henning, Robert J ^a   Johnson, Giffe T ^a   Coyle, Jayme P ^a   Harbison, Raymond D ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

Free oxygen radicals; Glutathione depletion; Protein adducts; Unsaturated aldehydes

Indexed keywords

ACROLEIN; BIOCIDE; CIGARETTE SMOKE; DIESEL FUEL; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GASOLINE; NITRIC OXIDE; OXYGEN RADICAL; PLASTIC;

AIR POLLUTANT; APOPTOSIS; ATHEROGENESIS; CARDIOMYOPATHY; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; COMBUSTION; COOKING; DIETARY INTAKE; DYSLIPIDEMIA; ENVIRONMENTAL FACTOR; ENZYME PHOSPHORYLATION; FRYING; HEART FAILURE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART MUSCLE NECROSIS; HUMAN; INGESTION; INHALATION; LONG TERM EXPOSURE; MUSCLE CELL; MYOCARDIAL DISEASE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW; SMOKING; TOXICOKINETICS; VASCULAR ENDOTHELIAL CELL; VASOSPASM; WATER POLLUTANT; WATER SUPPLY; WOOD; ANIMAL; CHEMICALLY INDUCED; CIGARETTE SMOKING; METABOLISM; PHYSIOLOGY; POLLUTANT;

ACROLEIN; ANIMALS; CARDIOVASCULAR DISEASES; CIGARETTE SMOKING; ENVIRONMENTAL POLLUTANTS; HUMANS; OXIDATIVE STRESS;

EID: 85010818094     PISSN: 15307905     EISSN: 15590259     Source Type: Journal    
DOI: 10.1007/s12012-016-9396-5     Document Type: Review

References (88)

1. Faroon, O., Roney, N., Taylor, J., Ashizawa, A., Lumpkin, M., & Plewak, D. (2008). Acrolein environmental levels and potential for human exposure. Toxicology and Industrial Health, 24, 543–564.
2. Faroon, O., Roney, N., Taylor, J., Ashizawa, A., Lumpkin, M., & Plewak, D. (2008). Acrolein health effects. Toxicology and Industrial Health, 24, 447–490.
3. Anderson, M., Hazen, S., Hsu, F., & Heinecke, J. (1997). Human neutrophils employ the myeloperoxidase-hydrogen peroxide-chloride system to convert hydroxy-amino acids into glycolaldehyde, 2-hydroxypropanal, and acrolein. A mechanism for the generation of highly reactive α-hydroxy and α, β-unsaturated aldehydes by phagocytes at sites of inflammation. Journal of Clinical Investigation, 99, 424–432.
4. De Woskin, R., Greenberg, M., Pepelko, W., & Strickland, J. (2003). Toxicological review of acrolein (cas no. 107-02-08) in support of summary information on the integrated risk information system (Iris). Washington, DC: US Environmental Protection Agency.
5. Abraham, K., Andres, S., Palavinskas, Berg K., Appel, K., & Lampen, A. (2011). Toxicology and risk assessment of acrolein in food. Molecular Nutrition & Food Research, 55, 1277–1290.
6. Conklin, D., Barski, O., Lesgards, J.-F., Juvan, P., Rezen, T., Rozman, D., et al. (2010). Acrolein consumption induces systemic dyslipidemia and lipoprotein modification. Toxicology and Applied Pharmacology, 15(243), 1–12.
7. Wang, G., Guo, Y., Vondriska, T., Zhang, J., Zhang, S., Tsai, L., et al. (2008). Acrolein consumption exacerbates myocardial ischemic injury and blocks nitric oxide-induced PKCε signaling and cardioprotection. Journal of Molecular and Cellular Cardiology, 44, 1016–1022.
8. Dwivedi, A., Johanson, G., Lorentzen, J., Palmberg, L., Sjogren, B., & Ernstgard, L. (2015). Acute effects of acrolein in human volunteers during controlled exposure. Inhalation toxicology, 27, 810–821.
9. Luo, J., Hill, B., Gu, Y., Cai, J., Srivastava, S., Bhatnagar, A., et al. (2007). Mechanisms of acrolein-induced myocardial dysfunction: Implications for environmental and endogenous aldehyde exposure. American Journal of Physiology Heart and Circulatory Physiology, 293, H3673–H3684.
10. Wheat, L., Haberzetti, P., Hellmann, J., Baba, S., Bertke, M., Lee, J., et al. (2011). Acrolein inhalation prevents VEGF-induced mobilization of Flk-1+/Sca-1+ cells in mice. Arteriosclerosis, Thrombosis, and Vascular Biology, 31, 1598–1606.
11. Brook, R., Rajagopalan, S., Pope, C., Brook, J., Bhatnagar, A., Diez-Roux, A., et al. (2010). Particulate matter air pollution and cardiovascular disease: An update to the scientific statement from the American Heart Association. Circulation, 121, 2331–2378.
12. Tonne, C., Melly, S., Mittleman, M., Coull, B., Goldberg, R., & Schwartz, J. (2007). A case-control analysis of exposure to traffic and acute myocardial infarction. Environmental Health Perspectives, 115, 53–57.
13. Agency for Toxic Substances and Disease Registry. Toxicological profile for acrolein. (2007). CAS#: 107-02-8, August.
14. Ghilarducci, D., & Tjeerdema, R. (1995). Fate and effects of acrolein. Reviews of Environmental Contamination and Toxicology, 144, 95–146.
15. Stevens, J., & Maier, C. (2008). Acrolein: Sources, metabolism, and biomolecular interactions relevant to human health and disease. Molecular Nutrition & Food Research, 52, 7–25.
16. Perez, C., Hazari, M., Ledbetter, A., Haykal-Coates, N., Carll, A., Cascio, W., et al. (2015). Acrolein inhalation alters arterial blood gases and triggers carotid body-mediated cardiovascular responses in hypertensive rats. Inhalation Toxicology, 27, 54–63.
17. Carmella, S., Chen, M., Zhang, Y., Zhang, S., Hatsukami, D., & Hecht, S. (2007). Quantitation of acrolein-derived 3-hydroxypropylmercapturic acid in human urine by liquid chromatography-atmospheric pressure chemical ionization-tandem mass spectrometry: Effects of cigarette smoking. Chemical Research in Toxicology, 20, 986–990.
18. World Health International Agency on Research on Cancer. (2005). Overall evaluations of carcinogenicity of 900 agents, mixtures and exposures to humans (pp. 1–82). Lyon. http://www-cie.iarc.fr/monoeval/crthall.html. Feb 15, 2005.
19. United States Department of Health and Human Services. (2014). The health consequences of smoking: 50 years of progress. A report of the surgeon general. Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health.
20. Breland, A., Spindle, T., Weaver, M., & Eissenberg, T. (2014). Science and electronic cigarettes: Current data, future needs. Journal of Addiction Medicine, 8, 223–233.
21. Counts, M., Morton, M., Laffoon, S., Cox, R., & Lipowicz, P. (2005). Smoke composition and predicting relationships for international commercial cigarettes smoked with three machine-smoking conditions. Regulatory Toxicology and Pharmacology, 41, 185–227.
22. Goniewicz, M., Knysak, J., Gawron, M., Kosmider, L., Sobczak, A., Kurek, J., et al. (2014). Levels of selected carcinogens and toxicants in vapour from electronic cigarettes. Tobacco Control, 23, 133–139.
23. Cheng, T. (2014). Chemical evaluation of electronic cigarettes. Tobacco Control, 23, ii11–ii17.
24. Etter, J. (2013). The electronic cigarette: An alternative to tobacco?. Atlanta: Elsevier.
25. Laugesen, M. (2008). Safety report on the Ruyan e-cigarette cartridge and inhaled aerosol. Health New Zealand Ltd., Christchurch. http://www.healthnz.co.nz/RuyanCartridgeReport30-Oct-08.pdf.
26. Uchiyama, S., Inaba, Y., & Kunugita, N. (2010). Determination of acrolein and other carbonyls in cigarette smoke using coupled silica cartridges impregnated with hydroquinone and 2,4-dinitrophenylhydrazine. Journal of Chromatography A, 1217, 4383–4388.
27. Lim, H. H., & Shin, H. S. (2013). Measurement of aldehydes in replacement liquids of electronic cigarettes by headspace gas chromatography-mass spectrometry. Bulletin of the Korean Chemical Society, 34, 2691–2696.
28. Uchiyama, S., Ohta, K., Inaba, Y., & Kunugita, N. (2013). Determination of carbonyl compounds generated from the e-cigarette using coupled silica cartridges impregnated with hydroquinone and 2,4-dinitrophenylhydrazine, followed by high-performance liquid chromatography. Analytical Sciences, 29, 1219–1222.
29. Breland, A., Soule, E., Lopez, A., Ramoa, C., El-Hellani, A., & Eissenberg, T. (2016). Electronic cigarettes: What are they and what do they do? Annals of the New York Academy of Sciences, 15, 1–26.
30. Ismahil, M., Hamid, T., Haberzetti, P., Gu, Y., Chandrasekar, B., Srivastava, S., et al. (2011). Chronic oral exposure to the aldehyde pollutant acrolein induces dilated cardiomyopathy. American Journal of Physiology Heart and Circulatory Physiology, 301, H2050–H2060.
31. Moghe, A., Ghare, S., Lamoreau, B., Mohammad, M., Barve, S., McClain, C., et al. (2015). Molecular mechanisms of acrolein toxicity: Relevance to human disease. Toxicological Sciences, 143, 242–255.
32. Srivastavaa, S., Sithu, S., Vladykovskayaa, E., Haberzettla, P., Hoetker, D., Siddiqui, M., et al. (2011). Oral exposure to acrolein exacerbates atherosclerosis in apoE-null mice. Atherosclerosis, 215, 301–308.
33. De Jonge, M., Huitema, A., Rodenhuis, S., & Beijnen, J. (2005). Clinical pharmacokinetics of cyclophosphamide. Clinical Pharmacokinetics, 44, 1135–1164.
34. Ewer, M., & Ewer, S. (2010). Cardiotoxicity of anticancer treatments: What the cardiologist needs to know. Nature Reviews Cardiology, 7, 564–567.
35. Takamoto, S., Sakura, N., & Namera, A. (2004). Monitoring of urinary acrolein concentration in patients receiving cyclophosphamide and isophamide. Journal of Chromatography, B: Analytical Technologies in the Biomedical and Life Sciences, 806, 59–63.
36. Conklin, D. (2016). Acute cardiopulmonary toxicity of inhaled aldehydes: Role of TRPA1. Annals of the New York Academy of Sciences, 1374, 59–67.
37. Conklin, D., Haberzetti, P., Jagatheesan, G., Kong, M., Hoyle, G. (2016). Role of TRPA1 in acute cardiopulmonary toxicity of inhaled acrolein, Toxicology and Applied Pharmacology. http://dx.doi.org/10.1016/j.taap.2016.08.028. (in press).
38. Bautista, D., Jordt, S.-E., Nikai, T., Tsuruda, P., Read, A., Poblete, J., et al. (2006). TRPA1 mediates the inflammatory actions of environmental irritants and proalgesic agents. Cell, 124, 1269–1282.
39. Andre, E., Campi, B., Materazzi, S., Trevisani, M., Amadesi, S., Massi, D., et al. (2008). Cigarette smoke—induced neurogenic inflammation is mediated by α, β-unsaturated aldehydes and the TRPA1 receptor in rodents. The Journal of Clinical Investigation, 118, 2574–2582.
40. Pozsgai, G., Bodkin, J., Graepel, R., Bevan, S., Andersson, D., & Brain, S. (2010). Evidence for the pathophysiological relevance of TRPA1 receptors in the cardiovascular system in vivo. Cardiovascular Research, 87, 760–768.
41. Earley, S. (2012). TRPA1 channels in the vasculature. British Journal of Pharmacology, 167, 13–22.
42. Hazari, M., Haykal-Coates, N., Winsett, D., Krantz, Q., Costa, D., & Frarraj, A. (2011). TRPA1 and sympathetic activation contribute to increased risk of triggered cardiac arrhythmias in hypertensive rats exposed to diesel exhaust. Environmental Health Perspectives, 119, 951–957.
43. Nemmar, A., Hoet, P., Vanquickenborne, B., Dinsdale, D., Thomeer, M., Hoylaerts, M., et al. (2002). Passage of inhaled particles into the blood circulation in humans. Circulation, 105, 411–414.
44. Negre-Salvayre, A., Coatrieux, C., Ingueneau, C., & Salvayre, R. (2008). Advanced lipid peroxidation end products in oxidative damage to proteins. Potential role in diseases and therapeutic prospects for the inhibitors. British Journal of Pharmacology, 153, 6–20.
45. Jacobs, A., & Marnett, L. (2010). Systems analysis of protein modification and cellular responses induced by electrophile stress. Accounts of Chemical Research, 43, 673–683.
46. Srivastava, M., Atwater, I., Glasman, M., Leighton, X., Goping, G., Caohuy, H., et al. (1999). Defects in inositol 1,4,5-trisphosphate receptor expression, Ca(2+) signaling, and insulin secretion in the anx7(±) knockout mouse. Proceedings of the National Academy of Sciences of the United States of America, 96, 13783–13788.
47. Keith, R., Haberzetti, P., Vladykovskaya, E., Bradford, G., Kaiserova, K., Srivastava, S., et al. (2009). Aldose reductase decreases endoplasmic reticulum stress in ischemic hearts. Chemico-Biological Interactions, 178, 242–249.
48. Maeshima, T., Honda, K., Chikazawa, M., Shibata, T., Kawai, Y., Akagawa, M., et al. (2012). Quantitative analysis of acrolein-specific adducts generated during lipid peroxidation—modification of proteins in vitro: Identification of Nτ-(3-propanal) histidine as the major adduct. Chemical Research in Toxicology, 25, 1384–1392.
49. Li, L., Jiang, L., Geng, C., Cao, J., & Zhong, L. (2008). The role of oxidative stress in acrolein-induced DNA damage in HepG2 cells. Free Radical Research, 42, 354–361.
50. Kehrer, P., & Biswal, S. (2000). The molecular effects of acrolein. Toxicological Sciences, 57, 6–15.
51. Liu, F., Li, X. L., Lin, T., He, D. W., Wei, G. H., Liu, J. H., et al. (2012). The cyclophosphamide metabolite, acrolein, induces cytoskeletal changes and oxidative stress in Sertoli cells. Molecular Biology Reports, 39, 493–500.
52. Jang, J., Bruse, S., Huneidi, S., Schrader, R., Monick, M., Lin, Y., et al. (2014). Acrolein-exposed normal human lung fibroblasts in vitro: Cellular senescence, enhanced telomere erosion, and degradation of werner’s syndrome protein. Environmental Health Perspectives, 122, 955–962.
53. Rom, O., Kaisaria, S., Aizenbuda, D., & Reznick, A. (2013). The effects of acetaldehyde and acrolein on muscle catabolism in C2 myotubes. Free Radical Biology and Medicine, 65, 190–200.
54. De Jarnett, N., Conklin, D., Riggs, D., Myers, J., O’Toole, T., Hamzeh, I., et al. (2014). Acrolein exposure is associated with increased cardiovascular disease risk. Journal of the American Heart Association, 3, e000934.
55. Perez, C., Ledbetter, A., Hazari, M., Haykal-Coates, N., Carll, A., Winsett, D., et al. (2013). Hypoxia stress test reveals exaggerated cardiovascular effects in hypertensive rats after exposure to the air pollutant acrolein. Toxicological Sciences, 132, 467–477.
56. McCall, M., Tang, J., Bielicki, J., & Forte, T. (1995). Inhibition of lecithin-cholesterol acyltransferase and modification of HDL apolipoproteins by aldehydes. Arteriosclerosis, Thrombosis, and Vascular Biology, 15, 1599–1606.
57. Watanabe, K., Nakazato, Y., Saiki, R., Igarashi, K., Kitada, M., & Ishii, I. (2013). Acrolein-conjugated low-density lipoprotein induces macrophage foam cell formation. Atherosclerosis, 227, 51–57.
58. Kim, C., Lee, S., Seo, K., Park, H., Yun, J., Bae, J., et al. (2010). Acrolein increases 5-lipoxygenase expression in murine macrophages through activation of ERK pathway. Toxicology and Applied Pharmacology, 245, 76–82.
59. O’Toole, T., Zheng, Y. T., Hellmann, J., Conklin, D., Barski, O., & Bhatnagar, A. (2009). Acrolein activates matrix metalloproteinases by increasing reactive oxygen species in macrophages. Toxicology and Applied Pharmacology, 236, 194–201.
60. Chadwick, A., Holme, R., Chen, Y., Thomas, M., Sorci-Thomas, M., Silverstein, R., et al. (2015). Acrolein impairs the cholesterol transport functions of high density lipoproteins. Plos ONE, 10, e0123138.
61. Conklin, D., Bhatnagara, A., Cowleyb, H., Johnsonc, G., Wiechmannc, R., Sayred, L., et al. (2006). Acrolein generation stimulates hypercontraction in isolated human blood vessels. Toxicology and Applied Pharmacology, 217, 277–288.
62. Hyvelin, J. M., Roux, E., Prevost, M. C., Savineau, J. P., & Marthan, R. (2000). Cellular mechanisms of acrolein-induced alterations in calcium signaling in airway smooth muscle. Toxicology and Applied Pharmacology, 164, 176–183.
63. Murata, F., Suzuki, S., Tsuyama, S., & Suganuma, T. (1985). Application of rapid freezing followed by freeze-substitution acrolein fixation for cytochemical studies of the rat stomach. The Histochemical Journal, 17, 967–980.
64. Biagini, R., Toraason, M., Lynch, D., & Winston, G. (1990). Inhibition of rat heart mitochondrial electron transport in vitro: Implications for the cardiotoxic action of allylamine or its primary metabolite, acrolein. Toxicology, 62, 95–106.
65. Biswal, S., Acquaah-Mensah, G., Datta, K., Wu, X., & Kehrer, J. (2002). Inhibition of cell proliferation and AP-1 activity by acrolein in human A549 lung adenocarcinoma cells due to thiol imbalance and covalent modifications. Chemical Research in Toxicology, 15, 180–186.
66. Vikman, P., Xu, C. B., & Edvinsson, L. (2009). Lipid-soluble cigarette smoking particles induce expression of inflammatory and extracellular-matrix-related genes in rat cerebral arteries. Vascular Health Risk Management, 5, 333–341.
67. Jaimes, E., De Master, E., Tian, R., & Raij, L. (2004). Stable compounds of cigarette smoke induce endothelial superoxide anion production via NADPH oxidase activation. Arteriosclerosis, Thrombosis, and Vascular Biology, 24, 1031–1036.
68. Misonou, Y., Asahi, M., Yokoe, S., Miyoshi, E., & Taniguchi, N. (2006). Acrolein produces nitric oxide through the elevation of intracellular calcium levels to induce apoptosis in human umbilical vein endothelial cells: Implications for smoke angiopathy. Nitric Oxide, 14, 180–187.
69. Cui, Y., Xie, X., Jia, F., He, J., Li, Z., Fu, M., et al. (2015). Ambient fine particulate matter induces apoptosis of endothelial progenitor cells through reactive oxygen species formation. Cellular Physiology and Biochemistry, 35, 353–363.
70. Tziakas, D., Chalikias, G., Parissis, J., Hatzinikolaou, E., Papadopoulos, E., Tripsiannis, G., et al. (2004). Serum profiles of matrix metalloproteinases and their tissue inhibitor in patients with acute coronary syndromes. International Journal of Cardiology, 94, 269–277.
71. Vasilyev, N., Williams, T., Brennan, M. L., Unzek, S., Zhou, X., Heinecke, J., et al. (2005). Myeloperoxidase-generated oxidants modulate left ventricular remodeling but not infarct size after myocardial infarction. Circulation, 112, 2812–2820.
72. Boor, P., & Ferrans, V. (1985). Ultrastructural alterations in allylamine cardiovascular toxicity. Late myocardial and vascular lesions. American Journal of Pathology, 121, 39–54.
73. Hochman, D., Collaco, C., & Brooks, E. (2014). Acrolein induction of oxidative stress and degranulation in mast cells. Environmental Toxicology, 29, 908–915.
74. Alano, C., Ying, W., & Swanson, R. (2004). Poly (ADP-ribose) polymerase-1-mediated cell death in astrocytes requires NAD+ depletion and mitochondrial permeability transition. Journal of Biological Chemistry, 279, 18895–18902.
75. Kauppinen, T., Chan, W., Suh, S., Wiggins, A., Huang, E., & Swanson, R. A. (2006). Direct phosphorylation and regulation of poly (ADP-ribose) polymerase-1 by extracellular signal-regulated kinases 1/2. Proceedings of the National Academy of Sciences of the United States of America, 103, 7136–7141.
76. Szabo, C., Zingarelli, B., O’Connor, M., & Salzman, A. (1996). DNA strand breakage, activation of poly (ADP-ribose) synthetase, and cellular energy depletion are involved in the cytotoxicity of macrophages and smooth muscle cells exposed to peroxynitrite. Proceedings of the National Academy of Sciences of the United States of America, 93, 1753–1758.
77. Ludwig, A., Behnke, B., Holtlund, J., & Hilz, H. (1988). Immunoquantitation and size determination of intrinsic poly (ADP-ribose) polymerase from acid precipitates. An analysis of the in vivo status in mammalian species and in lower eukaryotes. Journal of Biological Chemistry, 263, 6993–6999.
78. Virag, L., & Szabo, C. (2002). The therapeutic potential of poly (ADP-ribose) polymerase inhibitors. Pharmacological Reviews, 54, 375–429.
79. Zhang, S., Lin, Y., Kim, Y., Hande, M., Liu, Z., & Shen, H. (2007). c-Jun N-terminal kinase mediates hydrogen peroxide-induced cell death via sustained poly (ADP-ribose) polymerase-1 activation. Cell Death and Differentiation, 14, 1001–1010.
80. Ha, H., & Snyder, S. (1999). Poly (ADP-ribose) polymerase is a mediator of necrotic cell death by ATP depletion. Proceedings of the National Academy of Sciences of the United States of America, 96, 13978–13982.
81. Yu, S., Andrabi, S., Wang, H., Kim, N., Poirier, G., Dawson, T., et al. (2006). Apoptosis-inducing factor mediates poly (ADP-ribose) (PAR) polymer-induced cell death. Proceedings of the National Academy of Sciences of the United States of America, 103, 18314–18319.
82. McCluskey, J., Harbison, S., Johnson, G., & Harbison, R. (2012). PARP-1 inhibitor attenuates cocaine-induced hepatotoxicity. The Open Toxicology Journal, 5, 21–27.
83. Hall, K. W., Muro-Cacho, C., Abritis, A., Johnson, G. T., & Harbison, R. D. (2010). Attenuation of bromobenzene-induced hepatotoxicity by poly (ADP-Ribose) polymerase inhibitors. Research Communications in Molecular Pathology and Pharmacology, 122–123, 79–96.
84. Szabados, E., Literati-Nagy, P., Farkas, B., & Sumeti, B. (2000). BGP-15, a nicotinic amidoxime derivate protecting heart from ischemia reperfusion injury through modulation of poly (ADP-ribose) polymerase. Biochemical Pharmacology, 59, 937–945.
85. Faro, R., Toyoda, Y., McCully, J., Jagtap, P., Szabo, E., Virag, L., et al. (2002). Myocardial protection by PJ34, a novel potent poly (ADP-ribose) synthetase inhibitor. Annals of Thoracic Surgery, 73, 575–581.
86. Yang, Z., Zingarelli, B., & Szabo, C. (2000). Effect of genetic disruption of poly (ADP-ribose) synthetase on delayed production of inflammatory mediators and delayed necrosis during myocardial ischemia-reperfusion injury. Shock, 13, 60–66.
87. Pieper, A., Walles, T., Wei, G., Clements, E., Verma, A., Snyder, S., et al. (2000). Myocardial postischemic injury is reduced by polyADPripose polymerase-1 gene disruption. Molecular Medicine, 6, 271–282.
88. Pacher, P., Liaudet, L., Bai, P., Virag, L., Mabley, J., Hasko, G., et al. (2002). Activation of poly (ADP-ribose) polymerase contributes to the development of doxorubicin-induced heart failure. Journal of Pharmacology and Experimental Therapeutics, 300, 862–867.